Efficacy and safety of frontline therapy with "FCR" regimen for @entity1072 outside clinical trials: the Israeli XXXX study group experience.

@entity1 @entity137 @entity786 @entity1072 @entity3118
UNASSIGNED: This study aimed to evaluate the efficacy and safety of the @entity3118 - @entity786 -rituximab regimen for young physically fit @entity1 with @entity1072 in the "real-life" setting. We specifically focused on the impact of dose reduction on @entity1 outcomes. The @entity1 cohort consisted of 128 @entity1 with @entity1072 ( <=70 years) treated at 10 Israeli centers with frontline @entity3118 - @entity786 -rituximab. We defined reduced chemotherapy as  <=2/3 of the total indicated dose. @entity1 treated with rituximab were divided into two groups and compared, those who received full dosages of 375mg/m2 or 500mg/m2 and @entity1 given less than six cycles with either dose. Overall and clinical complete response rates (92.8% and 70.4%) as well as @entity137 and overall survival (median not reached at 6 years) were similar to other reported clinical trials, but progression free survival, was shorter (42.5 months). Almost 50% of @entity1 had some dose reduction of chemotherapy, 21% receiving  <=2/3 of the indicated dose, while close to 30% did not complete six cycles of rituximab. Reduced doses of chemotherapy and rituximab were independently associated with shorter progression free survival (hazard ratio-3.6, p<0.0001 for reduced chemotherapy; hazard ratio-2.5, p=0.003 for incomplete-treatment with rituximab). Achieving a complete response was associated with longer overall survival but was not linked to the given dose of chemoimmunotherapy. In younger physically fit @entity1 , frontline @entity3118 - @entity786 -rituximab therapy in the "real-life" setting, achieves long remissions (albeit shorter than in clinical trials) and prolonged overall survival. However, dose reductions are commonly administered and may impact outcome.
